Stoke Therapeutics Inc. (STOK)
| Bid | 7.47 |
| Market Cap | 407.21M |
| Revenue (ttm) | 36.55M |
| Net Income (ttm) | -88.98M |
| EPS (ttm) | -1.65 |
| PE Ratio (ttm) | -4.56 |
| Forward PE | -3.15 |
| Analyst | Buy |
| Ask | 7.91 |
| Volume | 9,347 |
| Avg. Volume (20D) | 839,809 |
| Open | 7.62 |
| Previous Close | 7.75 |
| Day's Range | 7.49 - 7.69 |
| 52-Week Range | 5.35 - 17.58 |
| Beta | 1.09 |
About STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...
Analyst Forecast
According to 6 analyst ratings, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 178.88% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Stoke Therapeutics to Present at Upcoming Investor Conferences in MarchBEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...
